Dear SIG members,
Hope all is well. Please see the email below regarding the international working group's Delphi Survey. Please reach out to Dawn if you have any questions.
Thanks,
Kui
Dear ISPE, please forward this email to the following SIGs:
Cell and gene therapy, drug-drug interaction, paediatrics, rare disease, vaccines
The International Working Group (IWG) on New Developments in Pharmacovigilance is inviting experts in pharmacovigilance from around the world to contribute to its research.
A study is underway to determine the types of data sources being used in day-to-day pharmacovigilance activities, and the strengths and limitations of these. Part of this research involves survey of experts in the field. We have identified you as someone who may be able to help us.
Below is a link to our questionnaire which we invite you to complete. It should take approximately twelve minutes. We do not want any patient level data to be shared.
https://www.surveymonkey.com/r/RTQMH6Y
Please complete the survey by Monday the 8th of July 2024. Any results received after this date will be disregarded. Additionally, if you have colleagues or contacts who may also be interested in participating in this study, please forward this email containing the link to the survey.
Please note that the privacy notice attached to this email must be read before you begin completing the survey. You will be asked to confirm that you have read the notice when you follow the survey link. You must click yes to proceed through the survey. The last question of the survey invites you to take part in a follow-up group discussion to explore in more depth the data sources available for pharmacovigilance tasks. Participation in the discussion group is entirely voluntary.
Data collected from the survey and the focused discussion will be synthesised in a reference guidance document which will be published as an open resource for pharmacovigilance personnel to use in their daily tasks.
We look forward to receiving your response. If you have any further questions, please do not hesitate to contact the co-ordinator of the IWG, Dawn Cooper (dawn.cooper@dsru.org) at The Drug Safety Research Unit.
If you would like to know more about the IWG please follow this link to our recent publication:
https://www.clinicaltherapeutics.com/article/S0149-2918(24)00002-X/fulltext
Many thanks
Dawn
Dr Dawn Cooper - Research Fellow/IWG Co-ordinator
Email:dawn.cooper@dsru.org
T: +44 (0)23 80 40 86 00
Drug Safety Research Unit,
Bursledon Hall, Blundell Lane,
Southampton, SO31 1AA, U.K.
www.dsru.org
------------------------------
Kui Huang PhD
Pfizer Inc
New York NY
+1 (212) 733-1309
------------------------------